23 studies on Tesamorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 4,946 published Tesamorelin COA source records from third-party laboratories, covering 1,316 publicly attributable vendor identities. Across 4,516 records with positive numeric purity, the arithmetic mean is 99.22%. 48 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 38 positive purity results are below 90%; 291 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $13.00 | $11.50–$14.50 | $2.60 | 3 sources · 3 offers |
| 10 mg | $22.00 | $20.00–$23.50 | $2.20 | 3 sources · 3 offers |
| 20 mg | $39.25 | $38.00–$40.50 | $1.96 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T04:28:01.524154+00:00. Calculation time is not a laboratory observation date.
Within that total, 1391 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 53 | 99.4% | 0 of 44 (0.0%) 0 0% / not detected · 0 wrong compound · 9 unclassified | Reveal with Pro → | |
| #2 | 74 | 99.38% | 1 of 65 (1.5%) 1 0% / not detected · 0 wrong compound · 9 unclassified | Reveal with Pro → | |
| #3 | 47 | 98.05% | 1 of 43 (2.3%) 1 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120484 (99.66%) · #120380 (99.1%) · #120478 (99.22%) · #120453 (99.24%) · #120362 (99.9%) · #120311 (99.02%)
The Canadian Society of Plastic Surgeons will host its 78th Annual Meeting in Toronto, ON, from June 3-7, 2025, with Dr. Nick Carr as President.
The premature termination of this 10-year observational study means that crucial long-term safety data for Tesamorelin in HIV-associated abdominal lipohypertrophy remains largely uncollected. This is significant becau…
The early termination of this study represents a missed opportunity to explore a potential therapeutic avenue for COPD-related muscle wasting, a condition with significant unmet medical needs. Tesamorelin, a synthetic…
Peripheral nerve injuries often result in debilitating long-term deficits, making effective therapeutic interventions critically important. If Tesamorelin proves successful in this trial, it could represent a novel ph…
The successful outcome of this trial could represent a significant advancement in managing HIV-associated neurocognitive disorders (HAND), which are a growing concern in the aging HIV population. If tesamorelin proves…
This analysis provides strong evidence that tesamorelin can be broadly considered for treating excess visceral adipose tissue in people with HIV, irrespective of the presence of dorsocervical fat. This simplifies clin…
These findings underscore the critical need for continued research into HIV's impact on the central nervous system, even in the era of effective ART, and highlight the multifaceted nature of neuropsychiatric complicat…
The termination of this Phase 4 clinical trial means a critical knowledge gap remains regarding the long-term ocular safety of tesamorelin in HIV-infected patients with diabetes. Understanding the potential risks or b…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single ru…
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this s…
This research provides anti-doping laboratories with a validated, highly sensitive protocol for detecting **CJC-1295** and similar banned peptides. For athletes using these substances, this significantly increases the…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…
Free, no account — handy when you're working with Tesamorelin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account